Marcy l'Étoile, April 24, 2019 – bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the three months ended March 31, 2019.
Asia
Europe, Middle East, Africa
North America
bioMérieux – First-Quarter 2019 Business Review
24 April, 2019
Holiday Shipping Schedule
15 April, 2019
Please be advised that bioMérieux, Inc. sites in Durham, NC, St. Louis, MO, Louisville, KY, and Lombard, IL will be closed on Friday, April 19, 2019 in observance of the upcoming holiday. We encourage you to place orders with these dates in mind.
University of Antwerp, bioMérieux, and Wellcome Trust to coordinate VALUE-Dx, a European Public-Private Partnership to fight antimicrobial resistance through diagnostics
02 April, 2019
The University of Antwerp, bioMérieux and Wellcome Trust today announced the launch of VALUE-Dx, the first Innovative Medicines Initiative (IMI) project initiated by six in vitro diagnostic companies who join forces with 20 non-industry partners to combat antimicrobial resistance (AMR) and improve patient outcomes.
Baxter and bioMérieux Announce Collaboration to Improve Identification and Treatment of Acute Kidney Injury
19 March, 2019
Baxter International Inc., a global leader in acute care, and bioMérieux, a world leader in the field of in vitro diagnostics, announced an agreement to develop future biomarkers with the goal to rapidly identify and inform treatment of acute kidney injury (AKI).
bioMérieux acquires Invisible Sentinel, a US-based company specialized in food and beverage molecular testing
07 February, 2019
bioMérieux, a global player in in vitro diagnostics and world leader in food microbiology testing, today announced the acquisition of Invisible Sentinel Inc.
Holiday Shipping Schedule
17 January, 2019
Please be advised that bioMérieux Inc. sites in Durham, NC, St. Louis, MO, Louisville, KY, and Lombard, IL will be closed on Monday, January 21, 2019 in observance of Martin Luther King Jr. Day.
BACT/ALERT® BPA and BPN have received 510(k) clearance from the FDA for quality control testing of LRAP units with BACT/ALERT® VIRTUO®
20 December, 2018
bioMérieux, a world leader in the field of in vitro diagnostics, announces that its culture bottles BACT/ALERT® BPA and BPN have received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for quality control testing of leukocyte-reduced apheresis platelet (LRAP) units with the BACT/ALERT® VIRTUO® fully automated blood culture system.
Holiday Shipping Schedule
05 December, 2018
Please be advised that all bioMérieux Inc. sites will be closed on December 24 - 25, 2018 and January 1, 2019 in observance of the upcoming holidays. We encourage you to place your orders with these dates in mind to ensure you receive products as needed.
Thanksgiving Shipping Schedule
13 November, 2018
Please be advised that bioMérieux Inc. sites in Durham, St. Louis, Louisville and Lombard will be closed on Thursday, November 22 and Friday, November 23.
bioMérieux launches the BIOFIRE® FILMARRAY® Pneumonia Panels with FDA clearance and CE Marking
13 November, 2018
bioMérieux, a world leader in the field of in vitro diagnostics, today announced the Food and Drug Administration (FDA) 510(k) clearance of the BIOFIRE® FILMARRAY® Pneumonia Panel and the CE-Mark of the BIOFIRE® FILMARRAY® Pneumonia Panel plus. The BIOFIRE® FILMARRAY® Pneumonia Panels aid in the diagnosis of lower respiratory tract infections.